Coverage and Reimbursement
Meniett therapy for Ménière’s disease is based on nearly 30 years of clinical research. It offers a safe, simple, and effective treatment for the vertigo symptoms of Ménière's disease.1-12 Though some insurance providers don’t cover it, we’ll work with your patient’s provider to help obtain coverage.
Reimbursement for the Meniett Device for Ménière’s Disease
Despite the significant clinical evidence supporting Meniett therapy for Ménière's disease, not all insurance providers automatically reimburse for the Meniett device. Your Ménière's disease patients should contact their insurance provider regarding coverage for Meniett therapy. Some managed care plans offer coverage for the Meniett device. Other insurance companies pay for the Meniett on a case-by-case basis.
Medicare covers medically necessary Meniett therapy for Ménière's disease. The Meniett device is considered durable medical equipment and is covered by Medicare nationally through the Durable Medical Equipment Regional Carriers (DMERC). The HCPCS code for the Meniett device is E2120.
Helping Your Ménière’s Disease Patients with Reimbursement
Medtronic's Therapy Access department may be able to help your Ménière's disease patients obtain coverage for the Meniett device. Please ask your patients to contact us at (877) 966-3350 or email us for more information.
You can also assist your Ménière’s disease patient in receiving reimbursement by writing a letter of medical necessity for his or her insurance provider. This may help increase the likelihood of your patient obtaining coverage for the Meniett device. Download a sample letter of medical necessity.
Financial Assistance for the Meniett Device for Ménière’s Disease
If insurance doesn’t cover your patient’s Meniett device, we have several no-interest payment options available. Our Meniett representative can explain these options to your Ménière's disease patients and answer their questions.
References
- Dornhoffer JL, King D. The effect of the Meniett device in patients with Ménière's disease: long-term results. Otol Neurotol 2008; 29(6):868-74.
- Mattox DE, Reichert M. Meniett device for Ménière's disease: use and compliance at 3 to 5 years. Otol Neurotol 2008; 29(1):29-32.
- Weining H, Fang L, Bo G, Jinmei Z. Clinical long-term effects of Meniett pulse generator for Ménière's disease. Acta Otolaryngol 2009; 129(8): 819-825.
- Barbara M, Monini S, Chiappini I, Filipo R. Meniett therapy may avoid vestibular neurectomy in disabling Ménière's disease. Acta Otolaryngol 2007; 127(11):1136-1141.
- Nabi S, Parnes LS. Bilateral Ménière’s disease. Curr Opin Otolaryngol Head Neck Surg 2009; 17:356-362.
- Thomsen J, Sass K, Ödkvist L, Arlinger S. Local over-pressure treatment reduces vestibular symptoms in patients with Ménière’s disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study. Otol Neurotol 2005; 26:68-73.
- Rajan GP, Din S, Atlas MD. Long-term effects of the Meniett device in Ménière’s disease: the Western Australian experience. J Laryngol Otol 2005; 119:391-395.
- Densert B, Sass K. Control of symptoms in patients with Ménière’s disease using middle ear applications: A two-year follow-up. Acta Otolaryngol 2001; 121(5):616-621.
- Gates GA, Green Jr. JD, Tucci DL, Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Ménière’s disease. Arch of Oto – HNS 2004; 130(6):718-725.
- Gates GA, Verrall A, Green Jr. JD, Tucci DL, Telian SA. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006; 132:1311-1316.
- Ödkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallquist J. Effects of middle ear pressure changes on clinical symptoms in patients with Ménière’s disease: A clinical, multicenter, placebo-controlled study. Acta Otolaryngol Suppl 2000; 543: 99-101.
- Densert B, Densert O, Arlinger S, Sass K, Ödkvist LM. Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière’s disease: A clinical placebo-controlled study. 1997; Am J Otol 1997; 18:726-733.
